Aura Biosciences AURA Income Statement (2020-2026)

NASDAQ AURA
$7.46 +0.09 (+1.22%)
As of: Sep 4, 2026 · 11:49 AM EDT
Reported Financials

Aura Biosciences Quarterly Income Statement

Periods 24 quarters
Latest Jun 2026

Aura Biosciences reported net income of -$46.10M for the quarter ended Jun 2026. This income statement covers 24 quarters of results from Sep 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating items
Research & DevelopmentR&D
6.37M7.98M8.28M9.51M11.29M13.16M14.40M15.12M15.43M20.28M17.05M16.88M17.04M22.33M23.34M22.88M22.18M21.90M27.96M30.75M
Selling, General & AdministrativeSG&A
2.53M3.65M4.54M4.31M4.76M4.45M5.04M5.16M5.06M4.50M5.26M5.88M6.20M5.47M5.69M5.73M5.73M5.34M6.91M17.32M
Other Operating ExpensesOther Opex
-0.01M-0.31M
Operating ExpensesOpex
8.89M11.63M12.81M13.82M16.05M17.61M19.44M20.28M20.49M24.78M22.31M22.76M23.23M27.81M29.04M28.61M27.91M27.24M34.87M48.07M
Operating IncomeOp. Inc
-8.89M-11.63M-12.81M-13.82M-16.05M-17.61M-19.44M-20.28M-20.49M-24.78M-22.31M-22.76M-23.23M-27.81M-29.04M-28.61M-27.91M-27.24M-34.87M-48.07M
EBIT
-8.89M-11.63M-12.81M-13.82M-16.05M-17.61M-19.44M-20.28M-20.49M-24.78M-22.31M-22.76M-23.23M-27.81M-29.04M-28.61M-27.91M-27.24M-34.87M-48.07M
Non-operating items
Non Operating Interest Expenses
0.01M
Non Operating Investment IncomeNon-Op. Investment Inc.
-0.01M
Other Non Operating IncomeOther Non Op Inc.
0.05M-0.04M0.06M-0.33M0.31M-0.01M-0.03M-0.01M-0.03M-0.03M-0.03M-0.03M3.17M-0.02M-0.04M-0.01M-2.66M0.00M0.15M
Non Operating IncomeNon Op. Inc.
0.06M-0.01M-0.02M0.35M0.15M1.05M1.98M1.98M1.98M2.79M2.65M2.42M2.23M2.00M1.57M1.64M1.80M1.69M1.19M2.46M
Net income details
EBT
-8.89M-11.63M-12.81M-13.82M-16.05M-17.61M-17.47M-18.30M-18.51M-21.99M-19.66M-20.34M-21.00M-25.81M-27.46M-26.97M-26.10M-26.37M-33.67M-45.61M
Tax ProvisionsTaxes
0.14M0.05M0.04M-18.33M0.02M0.05M0.03M-22.38M0.01M0.03M
Profit After TaxPAT
-8.84M-11.68M-12.84M-13.47M-15.92M-16.41M-17.47M-18.30M-18.51M-22.07M-19.71M-20.34M-21.04M-26.11M-27.48M-27.10M-26.13M-25.73M-33.69M-46.10M
Income from Continuing OperationsIncome (Continuing)
-8.89M-11.63M-12.81M-13.82M-16.05M-17.61M-17.47M-18.30M-18.51M-22.13M-19.71M-20.34M-21.04M-7.48M-27.48M-27.02M-26.13M-3.99M-33.69M-45.64M
Consolidated Net IncomeConsol Net Inc.
-8.89M-11.63M-12.81M-13.82M-16.05M-17.61M-17.47M-18.30M-18.51M-22.13M-19.71M-20.34M-21.04M-7.48M-27.48M-27.02M-26.13M-3.99M-33.69M-45.64M
Income towards Parent CompanyParent Net Inc
-8.89M-11.63M-12.81M-13.82M-16.05M-17.61M-17.47M-18.30M-18.51M-22.13M-19.71M-20.34M-21.04M-7.48M-27.48M-27.02M-26.13M-3.99M-33.69M-45.64M
Net Income towards Common StockholdersNet Income
-8.89M-11.63M-12.81M-13.82M-16.05M-17.61M-17.47M-18.30M-18.51M-22.13M-19.71M-20.34M-21.04M-7.48M-27.48M-27.02M-26.13M-3.99M-33.69M-45.64M
Additional items
EPS (Basic)
-20.15-2.25-0.44-0.47-0.55-0.59-0.46-0.48-0.48-0.56-0.40-0.41-0.42-0.15-0.55-0.47-0.40-0.07-0.50-0.48
EPS (Diluted)
-20.15-2.25-0.44-0.47-0.55-0.59-0.46-0.48-0.48-0.56-0.40-0.41-0.42-0.15-0.55-0.47-0.40-0.07-0.50-0.48
Shares Outstanding
0.44M5.16M29.21M29.25M29.27M29.94M37.78M37.86M38.19M39.62M49.45M49.55M49.66M49.65M50.13M58.02M65.94M60.34M67.45M94.86M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
0.44M5.16M29.21M29.25M29.27M29.94M37.78M37.86M38.19M39.62M49.45M49.55M49.66M49.65M50.13M58.02M65.94M60.34M67.45M94.86M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
0.44M5.16M29.22M29.27M29.28M29.94M37.80M38.09M38.22M39.62M49.50M49.58M49.78M50.00M50.23M62.07M62.99M63.59M64.15M103.48M
EBITDA
-8.89M-11.63M-12.81M-13.82M-16.05M-17.61M-19.44M-20.28M-20.49M-24.78M-22.31M-22.76M-23.23M-27.81M-29.04M-28.61M-27.91M-27.24M-34.87M-48.07M
Interest ExpensesInt Expense
0.01M
Tax Rate
-0.62%-0.25%-0.20%71.02%-0.07%-0.18%-0.10%84.86%-0.03%-0.06%